Crohn's Disease

Johnson & Johnson Q2 Earnings Preview: Can New Drugs Lift Sagging Stock?
Real-World Analysis Show Takeda's Alofisel Clinical Remission Rate At Six-Months
AbbVie's Upadacitinib Hits Primary Goal In Induction Study In Patients With Crohn's Disease
Real-World Analysis Show Takeda's Alofisel Clinical Remission Rate At Six-Months
AbbVie's Upadacitinib Hits Primary Goal In Induction Study In Patients With Crohn's Disease
How Crohn's Disease Opened My Eyes To The Healing Properties Of Cannabis
Galapagos Assumes Responsibility Of Late-Stage Filgotinib Trial In Crohn's Disease

Crohn's Disease Recent News

Cerecor's Crohn's Disease Candidate Shows Encouraging Response In Pretreated Patients
Almost Half of Crohn's Disease Patients Achieved Endoscopic Response After One Year ff Maintenance Treatment with AbbVie's Risankizumab
AbbVie Inc (NYSE: ABBV) has announced positive top-line results from the Phase 3 maintenance study, FORTIFY, showing Skyrizi (risankizumab) achieved the co-primary endpoints of endoscopic response and clinical remission at one year in Crohn's disease.
Eli Lilly's Mirikizumab Improves Fatigue in Crohn's Disease Patients
JNJ's Stelara Fails to Beat AbbVie's Humira In Crohn's Disease Patients
Eli Lil­ly Aban­dons IL-23 Psoriasis Program, Instead Will Focus On Ulcerative Colitis, Crohn's Disease Indications
Takeda Files Japan Marketing Application For Darvadstrocel In Crohn's Disease
Alabama Senate Committee Passes Medical Cannabis Legalization Bill
Alabama looks to join the growing list of states legalizing medical marijuana. The Yellowhammer State’s Senate committee on Wednesday said yes to a medical marijuana legalization bill, moving it to the full floor for review, reports Marijuana Moment.
Video: How Can Cannabis Help Crohn's Disease?
This article was originally published on The Medical Cannabis Community, and appears here with permission.
Cannabis And Crohn's Disease
RedHill Earns Long-Awaited Boost On Positive Crohn's Data
Celgene May Have Lost Positive Sentiment, But Its Growth Thesis Hasn't Gone Anywhere
Pipeline Bomb: Analysts Review Celgene's Crohn's Diseases Failure
Exclusive: RedHill BioPharma CEO Talks Steering His Company Through A Year Heavy With Potential Catalysts
Protagonist Therapeutics Spikes Sharply After Agreement With Janssen
Celgene Shares Higher On Positive Crohn's Patient Data
AbbVie Says Risankizumab More Effective Than Placebo For Crohn's Disease Management
Pfizer Receives FDA Approval For Cheaper Version Of Johnson & Johnson's Top Drug Remicade